Wedbush Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $15
Wedbush analyst Yun Zhong maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and lowers the price target from $16 to $15.
Read original at benzingaStocks · News reference
Rocket Pharma Announces Clinical Safety Update Regarding Initial Three Patients Treated Under Modified Protocol For Global, Pivotal Phase 2 Trial Of RP-A501 In Danon Disease
Initial three patients were treated safely; RP-A501 was well-tolerated with no TMA or capillary leak syndrome observedRocket is actively engaging with the FDA to align on the path to pivotal trial completion; regulatory
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 3, 2026, 11:14 AM
- Checked
- Aug 3, 2026, 11:14 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Rocket Pharmaceuticals Q2 Adj. EPS $(0.37) Misses $0.24 Estimate
Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $0.24 by 254.17 percent. This is a 40.32 percent increase over losses of $(0.62) per
Read original at benzingaRocket Pharmaceuticals Touts Positive Early Safety Data from Revised Genetic Therapy Trial
Rocket Pharmaceuticals announces positive early safety results for its RP-A501 Phase 2 trial in Danon disease and plans further FDA talks.
Read original at benzinga